Markets:

Overview

News

Currencies

International

Treasuries

Kura Oncology, Inc. - Common Stock (NQ:KURA)

8.960 +0.240 (+2.75%)

Streaming Delayed Price Updated: 12:37 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 21, 2024

Via Benzinga

This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

October 14, 2024

Via Benzinga

KURA Stock Earnings: Kura Oncology Beats EPS for Q2 2024 ↗

August 08, 2024

KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

7 ‘Death Cross’ Stocks That Could Be Contrarian Buys ↗

July 17, 2024

Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position.

Via InvestorPlace

Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

June 17, 2024

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

June 17, 2024

From FN Media Group LLC

Via GlobeNewswire

2 Incredible Growth Stocks to Buy Hand Over Fist ↗

May 08, 2024

These two healthcare growth stocks could have a lot more room to run.

Via The Motley Fool

Kura Oncology Inc. (NASDAQ: KURA) is a Stock Spotlight on 3/6

March 06, 2024

Via Investor Brand Network

Kura Oncology: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Earnings Outlook For Kura Oncology ↗

February 26, 2024

Via Benzinga

Kura Oncology Inc. (NASDAQ: KURA) Near the Top of Equities by Percentage Gain on 1/24

January 24, 2024

Via Investor Brand Network

KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024 ↗

May 02, 2024

KURA stock results show that Kura Oncology missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

Kura Makes Good On Its $150 Million Infusion And Shoots Up Another 15% ↗

January 30, 2024

The company just released promising results for its acute myeloid leukemia treatment.

Via Investor's Business Daily

Why Cancer-Drug Developer Kura Oncology Stock Is Up ↗

January 30, 2024

Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all...

Via Benzinga

General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday ↗

January 30, 2024

U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday.

Via Benzinga

Topics Stocks

A Preview Of Kura Oncology's Earnings ↗

November 01, 2023

Via Benzinga

Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 30, 2024

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales

Via Benzinga

Dow Edges Lower; US Composite PMI Rises In January ↗

January 24, 2024

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday. The Dow traded down 0.05% to 37,886.62 while the NASDAQ rose 0.59% to 15,517.32. The S&P 500...

Via Benzinga

Topics Stocks

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 24, 2024

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 24, 2024

Via Benzinga

Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today? ↗

January 24, 2024

Latest surge in Kura Oncology shares with a $150 million private placement announcement. Cash runway extended into 2027.

Via Benzinga

Textron Posts Upbeat Earnings, Joins ASML, Progressive And Other Big Stocks Moving Higher On Wednesday ↗

January 24, 2024

U.S. stocks traded higher, with the Nasdaq Composite gaining around 100 points on Wednesday. Shares of Textron Inc. (NYSE: TXT) rose during Wednesday’s session following upbeat quarterly earnings.

Via Benzinga

Topics Stocks

Kura Oncology Rockets 39% Before Unveiling Cancer Drug Test Results — Here's Why ↗

January 24, 2024

Kura Oncology is still a week out from unveiling the results for an AML drug. But shares soared Wednesday.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 24, 2024

Via Benzinga

Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst ↗

December 22, 2023

Mizuho initiated coverage on Kura Oncology Inc (NASDAQ: KURA), spotlighting the potential of ziftomenib as a first-in-class treatment for relapsed/refractory (r/r) NPM1-m acute myeloid leukemia...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 27, 2023

Via Benzinga

Kura Oncology's Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients ↗

October 18, 2023

Kura Oncology Inc (NASDAQ: KURA) announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is...

Via Benzinga

Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP® Technology ↗

September 13, 2023

Allarity Therapeutics (NASDAQ: ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer therapies coupled with companion diagnostics.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.